DN-015089

Primary objectives: ? To evaluate the safety and tolerability of DN015089 (hereinafter referred to as "DN089") for injection as a single agent in the treatment of subjects with advanced solid tumors, and to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) and/or recommended Phase II clinical trial dose (RP2D) of DN089 monotherapy. Secondary objectives: ? To evaluate the preliminary efficacy of DN089 monotherapy for advanced solid tumors. ? To evaluate the pharmacodynamic characteristics of DN089 monotherapy for advanced solid tumors, such as changes in cytokines, chemokines, etc. before and after administration. ? To evaluate the pharmacokinetic (PK) characteristics of DN089 monotherapy for intratumoral injection. Other objectives: ? To evaluate the changes in CD8+T cells in injection-side and non-injection-side tumor (if any) tissues before and after administration; ? To analyze the relationship between biomarkers in the blood and/or tumor tissues of subjects, such as viral infection (such as HPV infection, etc.), STING expression level and other biomarker expression levels and clinical efficacy. ? To analyze the relationship between dose-exposure-response.